These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12236844)

  • 1. Quinidine does not affect the renal clearance of moxonidine.
    Wise SD; Chan C; Schaefer HG; He MM; Pouliquen IJ; Mitchell MI
    Br J Clin Pharmacol; 2002 Sep; 54(3):251-4. PubMed ID: 12236844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steady state investigation of possible pharmacokinetic interactions of moxonidine and glibenclamide.
    Müller M; Weimann HJ; Eden G; Weber W; Michaelis K; Dilger C; Achtert G
    Eur J Drug Metab Pharmacokinet; 1993; 18(3):277-83. PubMed ID: 8149947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of food on the oral bioavailability of moxonidine.
    Theodor RA; Weimann HJ; Weber W; Müller M; Michaelis K
    Eur J Drug Metab Pharmacokinet; 1992; 17(1):61-6. PubMed ID: 1499598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of moxonidine after single and repeated daily doses in healthy volunteers.
    Trenk D; Wagner F; Jähnchen E; Plänitz V
    J Clin Pharmacol; 1987 Dec; 27(12):988-93. PubMed ID: 3437071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of pharmacokinetic interactions between moxonidine and digoxin.
    Pabst G; Weimann HJ; Weber W
    Clin Pharmacokinet; 1992 Dec; 23(6):477-81. PubMed ID: 1458765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.
    Bramer SL; Suri A
    Clin Pharmacokinet; 1999; 37 Suppl 2():41-51. PubMed ID: 10702886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism and disposition of moxonidine in Fischer 344 rats.
    He MM; Abraham TL; Lindsay TJ; Chay SH; Czeskis BA; Shipley LA
    Drug Metab Dispos; 2000 Apr; 28(4):446-59. PubMed ID: 10725314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of renal function on clinical pharmacokinetics of moxonidine.
    Kirch W; Hutt HJ; Plänitz V
    Clin Pharmacokinet; 1988 Oct; 15(4):245-53. PubMed ID: 3191647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine.
    Laganière S; Davies RF; Carignan G; Foris K; Goernert L; Carrier K; Pereira C; McGilveray I
    Clin Pharmacol Ther; 1996 Sep; 60(3):255-64. PubMed ID: 8841148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism and disposition of the antihypertensive agent moxonidine in humans.
    He MM; Abraham TL; Lindsay TJ; Schaefer HC; Pouliquen IJ; Payne C; Czeskis B; Shipley LA; Oliver SD; Mitchell MI
    Drug Metab Dispos; 2003 Mar; 31(3):334-42. PubMed ID: 12584161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered?
    Rameis H
    Int J Clin Pharmacol Ther Toxicol; 1985 Mar; 23(3):145-53. PubMed ID: 3997300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absolute bioavailability of moxonidine.
    Theodor R; Weimann HJ; Weber W; Michaelis K
    Eur J Drug Metab Pharmacokinet; 1991; 16(2):153-9. PubMed ID: 1936074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators.
    Majumdar S; Hippalgaonkar K; Srirangam R
    Drug Metab Dispos; 2009 Aug; 37(8):1718-25. PubMed ID: 19406953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine.
    Kharasch ED; Hoffer C; Whittington D; Sheffels P
    Clin Pharmacol Ther; 2003 Dec; 74(6):543-54. PubMed ID: 14663457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective antihypertensive therapy: blood pressure control with moxonidine.
    Prichard BN; Graham BR
    J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S38-48. PubMed ID: 8872298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine.
    Bleske BE; Carver PL; Annesley TM; Bleske JR; Morady F
    J Clin Pharmacol; 1990 Oct; 30(10):911-5. PubMed ID: 2229451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Itraconazole increases plasma concentrations of quinidine.
    Kaukonen KM; Olkkola KT; Neuvonen PJ
    Clin Pharmacol Ther; 1997 Nov; 62(5):510-7. PubMed ID: 9390107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
    Prichard BN; Owens CW; Graham BR
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mixed-effect modeling for detection and evaluation of drug interactions: digoxin-quinidine and digoxin-verapamil combinations.
    Bauer LA; Horn JR; Pettit H
    Ther Drug Monit; 1996 Feb; 18(1):46-52. PubMed ID: 8848820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects.
    Gimenez F; Foeillet E; Bourdon O; Weller S; Garret C; Bidault R; Singlas E
    Clin Pharmacokinet; 2004; 43(10):685-92. PubMed ID: 15244498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.